Patents by Inventor Christoph Van Amsterdam
Christoph Van Amsterdam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8058277Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in Claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolyties and/or antihypertonics. They can furthermore be employed as excitatory amino acid antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses.Type: GrantFiled: October 3, 2008Date of Patent: November 15, 2011Assignee: Merck Patent GmbHInventors: Oliver Schadt, Henning Böttcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7968551Abstract: Chromenoneindole derivatives of the formula (I), in which R1, R2, R3, R, A and B are as defined in Claim 1, and pharmaceutically usable prodrugs, derivatives, solvates, stereoisomers and salts thereof, exhibit particular actions on the central nervous system, in particular 5-HT reuptake-inhibiting and 5-HTx-agonistic and/or -antagonistic actions. They are distinguished by particularly high bioavailability and particularly high inhibition of 5-HT reuptake.Type: GrantFiled: March 8, 2004Date of Patent: June 28, 2011Assignee: Merck Patent GmbHInventors: Kai Schiemann, Henning Böttcher, Timo Heinrich, Günter Hölzemann, Christoph Van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Patent number: 7960413Abstract: Compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are suitable as ligands of 5 HT receptors.Type: GrantFiled: March 8, 2004Date of Patent: June 14, 2011Assignee: Merck Patent GmbHInventors: Oliver Schadt, Kai Schiemann, Christoph Van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7842695Abstract: Compounds of formula (I) and salts thereof, in which the following definitions apply: X is N or CH; R1 is H, A, Hal, (CH2)nHet, (CH2)nAr, C3-7-cycloalkyl, CF3, NO2, CN, C(NH)(OH), or OCF3; R2 is (CH2)nHet, (CH2)nAr, or C3-7-cycloalkyl, or CF3; R3 and R4 denote H or an organic radical. Compounds of formula (I) are useful as ligands of 5-HT receptors and useful in the treatment of disorders such as anxiety, depression, obsessive-compulsive disorder and pain.Type: GrantFiled: March 10, 2004Date of Patent: November 30, 2010Assignee: Merck Patent GmbHInventors: Oliver Schadt, Michael Arlt, Dirk Finsinger, Kai Schiemann, Christoph Van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7829565Abstract: Compounds of the formula (I), the use thereof for the preparation of a medicament for the treatment of diseases associated with the serotonin receptor and/or serotonin reuptake, in particular for the preparation of a medicament as anxiolytic, antidepressant, neuroleptic and/or antihypertonic and/or for positively influencing obsessive-compulsive disorder (OCD), sleeping disorders, tardive dyskinesia, learning disorders, age-dependent memory disorders, eating disorders, such as bulimia, and/or sexual dysfunctions. The compounds bind to the 5-HT1A receptor.Type: GrantFiled: May 24, 2004Date of Patent: November 9, 2010Assignee: Merck Patent GmbHInventors: Timo Heinrich, Henning Böttcher, Kai Schiemann, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Publication number: 20090291963Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolytics and/or antihypertonics.Type: ApplicationFiled: July 29, 2009Publication date: November 26, 2009Inventors: Oliver SCHADT, Henning Böttcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7598241Abstract: Novel compounds of the formula (I) in which R1, D, X, W, Y and T have the meaning indicated in Patent Claim (1), e.g. (II), are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.Type: GrantFiled: January 8, 2004Date of Patent: October 6, 2009Assignee: Merck Patent GmbHInventors: Dieter Dorsch, Bertram Cezanne, Werner Mederski, Christos Tsaklakidis, Johannes Gleitz, Christoph van Amsterdam
-
Patent number: 7579346Abstract: Novel compounds of the formula (I), in which D, W, X, Y, T, m and R1 have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.Type: GrantFiled: October 30, 2003Date of Patent: August 25, 2009Assignee: Merck Patent GmbHInventors: Dieter Dorsch, Bertram Cezanne, Werner Mederski, Christos Tsaklakidis, Hanns Wurziger, Johannes Gleitz, Christoph van Amsterdam
-
Patent number: 7572796Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolytics and/or antihypertonics. They can furthermore be employed as excitatory amino acid antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses.Type: GrantFiled: April 11, 2003Date of Patent: August 11, 2009Assignee: Merck Patent GmbHInventors: Oliver Schadt, Henning Böttcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7566709Abstract: Compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R5 and Q have the meanings indicated in Claim 1, are suitable as ligands of 5 HT receptors; as well as intermediate compounds of the formula (IA).Type: GrantFiled: March 8, 2004Date of Patent: July 28, 2009Assignee: Merck Patent GmbHInventors: Kai Schiemann, Oliver Schadt, Christoph Van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Publication number: 20090054459Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolyties and/or antihypertonics.Type: ApplicationFiled: October 3, 2008Publication date: February 26, 2009Inventors: Oliver Schadt, Henning Bottcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Gunter Holzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7432282Abstract: Novel indole derivatives of the formula (I), in which X, Y, R1, R1?, m and n have the meanings indicated in Patent Claim 1, have a strong affinity to the 5-HT1A and in some cases to the 5-HT1D receptors.Type: GrantFiled: October 30, 2003Date of Patent: October 7, 2008Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Günter Hölzemann, Kai Schiemann, Timo Heinrich, Henning Böttcher, Joachim Leibrock, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7427618Abstract: Novel compounds of the formula (I), in which R1, R2, R3, X and Y have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.Type: GrantFiled: January 30, 2004Date of Patent: September 23, 2008Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz, Christoph van Amsterdam
-
Patent number: 7329749Abstract: Compound of the formula (I) in which R1, R2 and alk are as defined in Claim 1, are potent 5-HT2A antagonist and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Hutington's disease, eating disorders, such as bulimia, anorexia nervosa, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD).Type: GrantFiled: December 24, 2001Date of Patent: February 12, 2008Assignee: Merck Patent GesellschaftInventors: Henning Boettcher, Gerd Bartoszyk, Juergen Harting, Christoph van Amsterdam, Christoph Seyfried
-
Publication number: 20080027140Abstract: The present invention relates to combinations of serotonin reuptake inhibitors and imidazoline I2 agonists as separate chemical units or both properties combined in a single molecule and to the use thereof for the preparation of medicaments for the treatment of depression, obsessive-compulsive disorders (OCDs), obsessive-compulsive spectrum disorders (OCSDs) and other anxiety states.Type: ApplicationFiled: December 15, 2004Publication date: January 31, 2008Applicant: MERCK PATENT GMBHInventors: Gerd Bartoszyk, Christoph Van Amsterdam, Henning Boettcher, Christoph Seyfried
-
Publication number: 20070299065Abstract: Novel compounds of the formula (I), in which T, E, R, R?, R?, R1, R2 and R2? have the meanings indicated in patent Claim 1, are suitable as antidiabetics.Type: ApplicationFiled: November 7, 2005Publication date: December 27, 2007Applicant: MERCK PATENT GMBHInventors: Werner Mederski, Christoph Van Amsterdam, Christa Burger, Hartmut Greiner
-
Patent number: 7262216Abstract: Novel benzofuran derivatives of the formula (I) in which R1, R2, X, Y, Z and m have the meanings indicated in Patent Claim 1, they have a strong affinity to the 5-HT1A receptors.Type: GrantFiled: January 10, 2004Date of Patent: August 28, 2007Assignee: Merck Patent GesellschaftInventors: Günter Hölzemann, Henning Böttcher, Kai Schiemann, Timo Heinrich, Joachim Leibrock, Christoph Van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7253202Abstract: Benzodioxepines of the formula (I) and physiologically tolerated salts and solvates thereof, in which R1, R2, R3, R4, A, B, a and b have the meanings indicated in claim 1, are ligands of the 5HT1A receptors and/or the 5HT4 receptors with simultaneously strong serotonin reuptake inhibition.Type: GrantFiled: November 27, 2003Date of Patent: August 7, 2007Assignee: Merck Patent GmbHInventors: Timo Heinrich, Henning Böttcher, Kai Schiemann, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Hartmut Greiner, Christoph Seyfried, Michel Brunet, Jean Zeiller, Jean Berthelon
-
Patent number: 7244846Abstract: Compounds of the formula (I), in which D, R1, R2 and n are defined in Claim 1, are potent 5-HT1A agonists and 5-HT reuptake inhibitors and are suitable for the treatment of depression, anxiety states, panic attacks, obsessive-compulsive disorders, psychiatric illnesses, cerebral infarction, cerebral ischaemia, tension states, side-effects in the treatment of high blood pressure, for the prophylaxis and therapy of cerebral illnesses, acromegaly, hypogonadism, secondary amenorrhoea, premenstrual syndrome, undesired puerperal lactation, pain, sleep disorders, narcolepsy, bipolar illnesses, mania, dementia, addiction illnesses, sexual dysfunction, eating disorders, obesity or fibromyalgiaType: GrantFiled: February 27, 2002Date of Patent: July 17, 2007Assignee: Merck Patent GmbHInventors: Dieter Dorsch, Henning Boettcher, Christoph van Amsterdam, Wilfried Rautenberg, Gerd Bartoszyk
-
Publication number: 20070105871Abstract: Compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R5 and Q have the meanings indicated in claim 1, are suitable as ligands of 5 HT receptors; as well as intermediate compounds of the formula (IA).Type: ApplicationFiled: March 8, 2004Publication date: May 10, 2007Inventors: Kai Schiemann, Oliver Schadt, Christoph Van Amsterdam, Gerd Bartoszyk, Christoph Seyfried